ERYTECH Pharma CEO and leadership

Gil Beyen is Chief Executive Officer of ERYTECH Pharma since May 2013 and President of ERYTECH Pharma Inc. since 2016. He served as ERYTECH’s Chairman of the Board from August 2012 until June 2019. Between 2000 and 2013, Mr. Beyen was Chief Executive Officer and Director of TiGenix (Euronext: TIG), a company he co-founded. He previously served as the head of the Life Sciences division of Arthur D. Little, an international management consulting firm, in Brussels. Mr. Beyen holds a MSc in Bioengineering from the University of Leuven (Belgium) and an M.B.A. from the University of Chicago.

I work in the field of cancer research and oncology drug development which is most rewardingSpecialties: Radiation Oncology, Oncology drug development, Translational researchExperienced oncology drug developer.Expertise in strategic planning, leading, implementing and reporting clinical projects for novel oncology drug candidates. Expertise in oncology translational medicine. Bridging preclinical and clinical through translational medicine strategies.Solid knowledge of regulatory landscape. Chairing multiple successful meetings with FDA, CHMP, and national Health Authorities in Europe.High level of credibility and respect among oncology world leaders Effective role in Biotech corporate governance, business development, and roadshow meetings

Eric Soyer has a more than 20 year experience in Management positions in financial and operational fields in public or private companies including eight years as Chief Financial Officer of EDAP TMS S.A., and Managing Director of the French affiliate Chief Financial Officer for a company operating nursing homes and post-care clinics, Financial and legal director for an insurance services company. He started his career as a financial controller and cost accountant for Michelin Group. Eric Soyer graduated from the ESC Clermont School of Management (France) and holds an M.B.A. from the University of Kansas and an Executive M.B.A. from the HEC Paris School of Management (France).

Stewart has more than 30 years of experience in development, cGMP manufacturing, quality systems and regulatory affairs for complex biologicals. For the past 20 years he has held executive level positions designing, implementing and operating the CMC and GMP manufacturing infrastructure for various public and private cell and gene therapy companies, including Sangamo BioSciences, StemCells Inc., Progenitor Cell Therapy, Xcyte Therapies, Osiris Therapeutics, and SyStemix, Inc. He has successfully led development, manufacture and clinical delivery of HSPCs, MSCs, NSCs, activated T cells, gene-modified T cells & gene-modified HSPCs. He also has extensive experience in regulatory affairs with successful cell and gene therapy submissions in US, Canada and Europe.

Gil Beyen is Chief Executive Officer of ERYTECH Pharma since May 2013 and President of ERYTECH Pharma Inc. since 2016. He served as ERYTECH’s Chairman of the Board from August 2012 until June 2019. Between 2000 and 2013, Mr. Beyen was Chief Executive Officer and Director of TiGenix (Euronext: TIG), a company he co-founded. He previously served as the head of the Life Sciences division of Arthur D. Little, an international management consulting firm, in Brussels. Mr. Beyen holds a MSc in Bioengineering from the University of Leuven (Belgium) and an M.B.A. from the University of Chicago.